In brief
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
The company has two areas of focus:
- a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s Disease.
- a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure and viral disease including Ebola, Marburg and COVID-19.